SSR Mining Inc. (SSRM) — Earnings Call X-Ray
Our AI read all 28 of SSRM's earnings calls (2018–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
C
Q3 2024
Calls Analyzed
28
2018–2025
Avg Candor
7.1/9
evasion 2.4/9
Call-by-call analysis
🔒 Q4 2024 earnings call
2025-02-18
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q4 2024 call grade is ready
The full 37-point AI read of SSRM's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
C
Q3 2024 earnings call
2024-11-06
move ±21%
Management gave no formal guidance against steady demand and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: mixedDemand: stableMargins: contractingPricing: raisingCapex: increasing 1 analysts · 3 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q2 2024 earnings call
2024-07-31
move ±18.9%
Management held guidance steady against steady demand. The delivery was rich in specifics, frequently evasive.
Guidance: maintainedDemand: stablePricing: stableHeadcount: flatCapex: increasing 1 analysts · 4 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q1 2024 earnings call
2024-05-08
move ±9.1%
Management held guidance steady against steady demand and contracting margins. The delivery was unusually candid, frequently evasive.
Guidance: maintainedDemand: stableMargins: contractingCapex: increasing 3 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
F
Q4 2023 earnings call
2024-03-01
move ±24.7%
Management withdrew guidance against contracting margins. The delivery was unusually candid, frequently evasive, visibly under pressure.
Guidance: withdrawnMargins: contractingCapex: decreasing 1 analysts · 4 questions
⚑ Critic ammunition⚑ Question left hanging
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
D
Q3 2023 earnings call
2023-11-01
move ±12%
Management lowered guidance against steady demand and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: loweredDemand: stableMargins: contractingPricing: stableCapex: increasing 3 analysts · 14 questions
⚑ Critic ammunition⚑ Question left hangingDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
B
Q2 2023 earnings call
2023-08-02
move ±8%
Management held guidance steady against steady demand. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: stableMargins: stablePricing: stableCapex: decreasing 1 analysts · 4 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up aheadDirection beats results
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
YES Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
B+
Q1 2023 earnings call
2023-05-04
move ±10.2%
Management held guidance steady against steady demand. The delivery was unusually candid, rich in specifics, relaxed under questioning.
Guidance: maintainedDemand: stableMargins: stablePricing: stableCapex: increasing 2 analysts · 7 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q4 2022 |
2023-02-22 |
B |
maintained | stable | contracting |
7/9 |
2/9 |
| Q3 2022 |
2022-11-08 |
D |
lowered | stable | contracting |
7/9 |
2/9 |
| Q2 2022 |
2022-08-02 |
C |
lowered | stable | contracting |
8/9 |
2/9 |
| Q1 2022 |
2022-05-04 |
B |
maintained | stable | contracting |
7/9 |
2/9 |
| Q4 2021 |
2022-02-24 |
B |
maintained | stable | stable |
7/9 |
2/9 |
| Q3 2021 |
2021-11-03 |
C+ |
lowered | stable | expanding |
7/9 |
2/9 |
| Q2 2021 |
2021-08-05 |
B |
maintained | stable | expanding |
7/9 |
2/9 |
| Q1 2021 |
2021-05-06 |
B+ |
maintained | stable | stable |
6/9 |
2/9 |
| Q4 2020 |
2021-02-17 |
B |
maintained | stable | stable |
7/9 |
2/9 |
| Q3 2020 |
2020-11-12 |
B |
maintained | stable | stable |
7/9 |
2/9 |
| Q2 2020 |
2020-08-07 |
B+ |
maintained | stable | unclear |
7/9 |
2/9 |
| Q1 2020 |
2020-05-15 |
B+ |
maintained | stable | stable |
8/9 |
2/9 |
| Q4 2019 |
2020-02-21 |
A |
maintained | stable | expanding |
7/9 |
1/9 |
| Q3 2019 |
2019-11-06 |
B |
maintained | accelerating | expanding |
7/9 |
2/9 |
| Q2 2019 |
2019-08-09 |
B+ |
raised | stable | expanding |
7/9 |
2/9 |
| Q1 2019 |
2019-05-11 |
B |
maintained | accelerating | expanding |
7/9 |
2/9 |
| Q4 2018 |
2019-02-22 |
A |
raised | stable | expanding |
7/9 |
2/9 |
| Q3 2018 |
2018-11-10 |
A |
raised | stable | expanding |
7/9 |
3/9 |
| Q2 2018 |
2018-08-10 |
B+ |
raised | stable | expanding |
7/9 |
2/9 |
| Q1 2018 |
2018-05-11 |
B+ |
maintained | stable | stable |
8/9 |
1/9 |
Research question bank — earlier calls
During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of SSRM's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.
B+
Q2 2018 earnings call
2018-08-10
7 more research questions answered NO
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← SSRI All “S” companies
SSS →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.